This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (April 2011)
Chemical and physical data
C 30 H 25 Cl 2 F 3 N 4 O S
Molar mass 617.51 g/mol
3D model (
TM-38837 is a small molecule inverse agonist/ antagonist of the CB, with peripheral selectivity. It is being developed for the treatment of 1 cannabinoid receptor obesity and metabolic disorders by 7TM Pharma. The company has announced  phase I clinical trials.
TM-38837 is among the first of a new generation of
cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB 1 receptor antagonists such as rimonabant. 
See also [ edit ]
References [ edit ]
^ https://web.archive.org/web/20110707065905/http://www.7tm.com/. Archived from the original on July 7, 2011 . Retrieved . January 18, 2011
^ Hung, M. S.; Chang, C. P.; Li, T. C.; Yeh, T. K.; Song, J. S.; Lin, Y.; Wu, C. H.; Kuo, P. C.; Amancha, P. K.; Wong, Y. C.; Hsiao, W. C.; Chao, Y. S.; Shia, K. S. (2010). "Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a Potential Peripheral Cannabinoid-1 Receptor Inverse Agonist". ChemMedChem. 5 (9): 1439–1443. PMID 20652930. doi: 10.1002/cmdc.201000246.
External links [ edit ]